LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Search

Perrigo Co PLC

Затворен

СекторЗдравеопазване

10.6 -2.12

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.5

Максимум

10.83

Ключови измерители

By Trading Economics

Приходи

1B

-390M

Продажби

-140M

969M

EPS

0.43

Дивидентна доходност

9.91

Марж на печалбата

-40.229

Служители

8,100

EBITDA

1.4B

118M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+46.65% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

9.91%

2.34%

Следващи печалби

5.08.2026 г.

Следваща дата на дивидент

16.06.2026 г.

Следваща дата на екс-дивидент

29.05.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-36M

1.5B

Предишно отваряне

12.72

Предишно затваряне

10.6

Настроения в новините

By Acuity

17%

83%

25 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Perrigo Co PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.07.2025 г., 13:01 ч. UTC

Придобивния, сливания и поглъщания

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

14.07.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

14.07.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

14.07.2025 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

14.07.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

14.07.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

14.07.2025 г., 12:30 ч. UTC

Придобивния, сливания и поглъщания

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Сравнение с други в отрасъла

Ценова промяна

Perrigo Co PLC Прогноза

Ценова цел

By TipRanks

46.65% нагоре

12-месечна прогноза

Среден 16 USD  46.65%

Висок 17 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Perrigo Co PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

25.22 / 26.85Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

25 / 345 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
help-icon Live chat